Metraipolis › archive › dc_406804da1bce

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy — Europe PMC PMID:41471300

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41471300
DOI
10.3390/ph18121811
License (as archived)
solo-consultazione
Archived
2026-11-08T05:31:51.773Z
SHA-256 of the archived text
df11d47ed78def6054b54e1af0a3b1f8e90213d6c297c0b8190db8ac5489f4f6
Stable URL of this page
https://metraipolis.com/documento/dc_406804da1bce

How to cite

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy — Europe PMC PMID:41471300 — Europe PMC (en), https://europepmc.org/article/MED/41471300 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_406804da1bce (Metraipolis archive dc_406804da1bce, sha256 df11d47ed78def6054b54e1af0a3b1f8e90213d6c297c0b8190db8ac5489f4f6)
BibTeX
@misc{dc406804da1bce,
  title = {Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy — Europe PMC PMID:41471300},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41471300},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_406804da1bce; sha256 df11d47ed78def6054b54e1af0a3b1f8e90213d6c297c0b8190db8ac5489f4f6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41471300. Agents can read the archived copy with the MCP tool read_document.